title: Association of calcium antagonist use with lower hemoglobin levels in hemodialysis patients.
abstract: OBJECTIVE
  Objective of the present study was to investigate whether calcium antagonist use is associated with lower hemoglobin levels and/or higher erythropoiesis stimulating agent (ESA) requirement in hemodialysis patients.
  
  
  METHODS
  A total of 130 adult hemodialysis patients were classified into two groups based on calcium antagonist usage for a period of at least 3 months as calcium antagonist users and calcium antagonist non-users. The two groups were compared cross-sectionally in a retrospective manner in terms of demographics, chronic kidney disease aetiologies, Charlson's Comorbidty Index, blood pressure, type of dialysis access, interdialytic body weight gain, cardiothoracic index, complete blood count, biochemistry, regular medication use and consumption of ESA. All independent variables that were different between the groups were subjected to logistic regression analysis. Linear regression analysis with dependent variable of hemoglobin value was also performed
  
  
  RESULTS
  ESA consumption and blood pressure were higher, diabetic nephropathy, doxazosin and ACE inhibitor use were more frequent, and hemoglobin was lower in the calcium antagonist users. After logistic regression analysis, diabetic nephropathy, doxazosin use, ACE inhibitor use and lower hemoglobin were associated with calcium antagonist use. After lineer regression analysis, Age, BMI, gender, predialysis creatinine value, dialysis duration, systolic and diastolic blood pressure, doxazosin use, diabetes mellitus and diabetic nephropathy were not related with hemoglobin value. But, higher amount of ESA consumption, ACE inhibitor use and calcium antagonist use were significantly associated with lower hemoglobin value.
  
  
  CONCLUSIONS
  CA use was associated with lower hemoglobin levels in our hemodialysis patient population.
authors.affiliation: Department of Internal Medicine, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey - malicikrikcioglu@yahoo.com.
authors.forename: M A
authors.initials: MA
authors.lastname: Cikrikcioglu
authors.forename: A A
authors.initials: AA
authors.lastname: Ozdemir
authors.forename: Y
authors.initials: Y
authors.lastname: Sekin
authors.forename: B
authors.initials: B
authors.lastname: Yalcin
authors.forename: M
authors.initials: M
authors.lastname: Altay
authors.forename: A
authors.initials: A
authors.lastname: Gundogdu
authors.forename: S N
authors.initials: SN
authors.lastname: Erkal
authors.forename: R
authors.initials: R
authors.lastname: Kazancioglu
authors.forename: R
authors.initials: R
authors.lastname: Erkoc
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000628:therapy; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D006454:Hemoglobins